Literature DB >> 23322277

Overexpression of CK20, MAP3K8 and EIF5A correlates with poor prognosis in early-onset colorectal cancer patients.

Berrin Tunca1, Gulcin Tezcan, Gulsah Cecener, Unal Egeli, Abdullah Zorluoglu, Tuncay Yilmazlar, Secil Ak, Omer Yerci, Ersin Ozturk, Gorkem Umut, Turkkan Evrensel.   

Abstract

PURPOSE: Due to ethnic, genetic and environmental factors, the clinical and molecular characteristics of Turkish colorectal cancer (CRC) patients are different from those of Western populations. The aim of this study was to clarify the relevant alterations of gene expression associated with colorectal carcinogenesis in early-onset patients and to identify specific biomarkers that could provide novel therapeutic molecular targets in this population.
METHODS: The expression profiles of 114 different genes were evaluated using mRNA PCR arrays in 39 tumors and 20 surgical margin tissue samples from 39 sporadic CRC patients diagnosed at less than 50 years of age.
RESULTS: The expression levels of IMPDH2, CK20, MAP3K8 and EIF5A were strongly up-regulated in CRC tissues compared with normal colorectal tissues (p < 0.05). The highly significant expression ratios of CK20, MAP3K8 and EIF5A observed in the colorectal tumors of patients predicted recurrence (p < 0.05). The expression of IMPDH2, CK20, MAP3K8 and EIF5A was significantly higher in the tumors of patients with short median survival (log-rank p value < 0.05). Progression-free survival was also significantly increased in patients with low expression of the EIF5A gene compared with those who exhibited high expression of this gene (log-rank p value < 0.05).
CONCLUSION: We demonstrated that high CK20, MAP3K8 and EIF5A expression levels were significant prognostic factors for poor overall survival in CRC patients. Further studies and validations are required; these genes may provide novel therapeutic molecular targets for CRC treatment, as well as new directions for the development of anticancer drugs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23322277     DOI: 10.1007/s00432-013-1372-x

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  54 in total

1.  Expression of cytokeratin 20 redefines urothelial papillomas of the bladder.

Authors:  P Harnden; N Mahmood; J Southgate
Journal:  Lancet       Date:  1999-03-20       Impact factor: 79.321

2.  Colorectal carcinoma in patients under the age of 30 years: a review of 11 cases.

Authors:  O G Ajao; M O Adenuga; J K Ladipo
Journal:  J R Coll Surg Edinb       Date:  1988-10

Review 3.  Molecular targets of guanine nucleotides in differentiation, proliferation and apoptosis.

Authors:  J A Yalowitz; H N Jayaram
Journal:  Anticancer Res       Date:  2000 Jul-Aug       Impact factor: 2.480

4.  Clinicopathological and molecular biological features of colorectal cancer in patients less than 40 years of age.

Authors:  J T Liang; K C Huang; A L Cheng; Y M Jeng; M S Wu; S M Wang
Journal:  Br J Surg       Date:  2003-02       Impact factor: 6.939

Review 5.  Tpl-2/Cot and COX-2 in breast cancer.

Authors:  Zuzana Krcova; Jiri Ehrmann; Veronika Krejci; Aris Eliopoulos; Zdenek Kolar
Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub       Date:  2008-06       Impact factor: 1.245

6.  Identification of occult tumor cells in node negative lymph nodes of colorectal cancer patients by cytokeratin 20 gene and protein expression.

Authors:  S Lassmann; M Bauer; R Rosenberg; H Nekarda; R Soong; R Rüger; H Höfler; M Werner
Journal:  Int J Colorectal Dis       Date:  2003-09-10       Impact factor: 2.571

7.  Benzamide riboside induced mitochondrial mediated apoptosis in human lung cancer H520 cells.

Authors:  Neeru Khanna; H N Jayaram; Neeta Singh
Journal:  Life Sci       Date:  2004-05-28       Impact factor: 5.037

8.  Overexpression of EIF-5A2 is an independent predictor of outcome in patients of urothelial carcinoma of the bladder treated with radical cystectomy.

Authors:  Wei Chen; Jun-Hang Luo; Wen-Feng Hua; Fang-Jian Zhou; Marie C Lin; Hsiang-Fu Kung; Yi-Xin Zeng; Xin-Yuan Guan; Dan Xie
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01-20       Impact factor: 4.254

9.  Young age is not a poor prognostic marker in colorectal cancer.

Authors:  Y F Chung; K W Eu; D Machin; J M Ho; D C Nyam; A F Leong; Y H Ho; F Seow-Choen
Journal:  Br J Surg       Date:  1998-09       Impact factor: 6.939

10.  COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.

Authors:  Cory M Johannessen; Jesse S Boehm; So Young Kim; Sapana R Thomas; Leslie Wardwell; Laura A Johnson; Caroline M Emery; Nicolas Stransky; Alexandria P Cogdill; Jordi Barretina; Giordano Caponigro; Haley Hieronymus; Ryan R Murray; Kourosh Salehi-Ashtiani; David E Hill; Marc Vidal; Jean J Zhao; Xiaoping Yang; Ozan Alkan; Sungjoon Kim; Jennifer L Harris; Christopher J Wilson; Vic E Myer; Peter M Finan; David E Root; Thomas M Roberts; Todd Golub; Keith T Flaherty; Reinhard Dummer; Barbara L Weber; William R Sellers; Robert Schlegel; Jennifer A Wargo; William C Hahn; Levi A Garraway
Journal:  Nature       Date:  2010-11-24       Impact factor: 49.962

View more
  21 in total

Review 1.  Targeting the polyamine-hypusine circuit for the prevention and treatment of cancer.

Authors:  Shima Nakanishi; John L Cleveland
Journal:  Amino Acids       Date:  2016-06-29       Impact factor: 3.520

Review 2.  The translation factor eIF5A and human cancer.

Authors:  Michael B Mathews; John W B Hershey
Journal:  Biochim Biophys Acta       Date:  2015-05-13

3.  Eukaryotic Translation Initiation Factor 5A (EIF5A) Regulates Pancreatic Cancer Metastasis by Modulating RhoA and Rho-associated Kinase (ROCK) Protein Expression Levels.

Authors:  Ken Fujimura; Sunkyu Choi; Meghan Wyse; Jan Strnadel; Tracy Wright; Richard Klemke
Journal:  J Biol Chem       Date:  2015-10-19       Impact factor: 5.157

4.  Overexpression of eIF3e is correlated with colon tumor development and poor prognosis.

Authors:  Zhi Li; Shengtao Lin; Tao Jiang; Jingtao Wang; Huijun Lu; Huamei Tang; Mujian Teng; Junwei Fan
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

5.  Elevated expression of IMPDH2 is associated with progression of kidney and bladder cancer.

Authors:  Jun Zou; Zhaodong Han; Liang Zhou; Chao Cai; Hongwei Luo; Yaqiang Huang; Yuxiang Liang; Huichan He; Funeng Jiang; Cong Wang; Weide Zhong
Journal:  Med Oncol       Date:  2014-12-03       Impact factor: 3.064

6.  TPL2 kinase regulates the inflammatory milieu of the myeloma niche.

Authors:  Chelsea Hope; Samuel J Ollar; Erika Heninger; Ellen Hebron; Jeffrey L Jensen; Jaehyup Kim; Ioanna Maroulakou; Shigeki Miyamoto; Catherine Leith; David T Yang; Natalie Callander; Peiman Hematti; Marta Chesi; P Leif Bergsagel; Fotis Asimakopoulos
Journal:  Blood       Date:  2014-04-10       Impact factor: 22.113

Review 7.  Molecular approach to genetic and epigenetic pathogenesis of early-onset colorectal cancer.

Authors:  Gulcin Tezcan; Berrin Tunca; Secil Ak; Gulsah Cecener; Unal Egeli
Journal:  World J Gastrointest Oncol       Date:  2016-01-15

8.  The hypusine cascade promotes cancer progression and metastasis through the regulation of RhoA in squamous cell carcinoma.

Authors:  T Muramatsu; K-I Kozaki; S Imoto; R Yamaguchi; H Tsuda; T Kawano; N Fujiwara; M Morishita; S Miyano; J Inazawa
Journal:  Oncogene       Date:  2016-04-04       Impact factor: 9.867

9.  Colorectal cancers mimic structural organization of normal colonic crypts.

Authors:  Laura Cernat; Cristina Blaj; Rene Jackstadt; Lydia Brandl; Jutta Engel; Heiko Hermeking; Andreas Jung; Thomas Kirchner; David Horst
Journal:  PLoS One       Date:  2014-08-11       Impact factor: 3.240

10.  MAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas.

Authors:  Tina Gruosso; Camille Garnier; Sophie Abelanet; Yann Kieffer; Vincent Lemesre; Dorine Bellanger; Ivan Bieche; Elisabetta Marangoni; Xavier Sastre-Garau; Virginie Mieulet; Fatima Mechta-Grigoriou
Journal:  Nat Commun       Date:  2015-10-12       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.